Extract

This was a multicenter, Phase 1, standard 3+3 dose-escalation study to evaluate the safety and anti-neoplastic activity of moxetumomab pasudotox in relapsed or refractory participants with chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL) or Small Lymphocytic Lymphoma (SLL).

Inclusion criteria

• Leukemia, Lymphoma, Chronic Lymphocytic,Leukemia, Prolymphocytic Leukemia, Small,Lymphocytic Lymphoma, Moxetumomab Pasudotox

Links

• nct
• ictrp